Abacus FCF Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.9M | Sell |
59,268
-42,595
| -42% | -$9.45M | 2.9% | 8 |
|
|
2025
Q4 | $23.3M | Sell |
101,863
-24,405
| -19% | -$5.56M | 3.04% | 4 |
|
|
2025
Q3 | $29.2M | Buy |
126,268
+3,600
| +3% | +$733K | 3.89% | 1 |
|
|
2025
Q2 | $22.8M | Buy |
122,668
+14,536
| +13% | +$2.7M | 3.19% | 4 |
|
|
2025
Q1 | $22.7M | Buy |
108,132
+2,959
| +3% | +$575K | 3.56% | 2 |
|
|
2024
Q4 | $18.7M | Buy |
105,173
+41,802
| +66% | +$7.69M | 2.46% | 3 |
|
|
2024
Q3 | $12.5M | Buy |
63,371
+2,555
| +4% | +$477K | 2.9% | 2 |
|
|
2024
Q2 | $10.4M | Sell |
60,816
-3,149
| -5% | -$522K | 2.59% | 3 |
|
|
2024
Q1 | $11.6M | Buy |
63,965
+5,073
| +9% | +$874K | 2.91% | 2 |
|
|
2023
Q4 | $9.13M | Buy |
58,892
+34,588
| +142% | +$5.04M | 2.65% | 3 |
|
|
2023
Q3 | $3.62M | Buy |
24,304
+1,208
| +5% | +$177K | 1.93% | 8 |
|
|
2023
Q2 | $3.11M | Sell |
23,096
-151
| -0.6% | -$22.1K | 1.57% | 9 |
|
|
2023
Q1 | $3.7M | Buy |
23,247
+7,867
| +51% | +$1.2M | 1.99% | 4 |
|
|
2022
Q4 | $2.49M | Sell |
15,380
-345
| -2% | -$52.9K | 1.62% | 6 |
|
|
2022
Q3 | $2.11M | Sell |
15,725
-1,150
| -7% | -$165K | 1.45% | 7 |
|
|
2022
Q2 | $2.58M | Sell |
16,875
-18,172
| -52% | -$2.78M | 1.58% | 7 |
|
|
2022
Q1 | $5.68M | Buy |
35,047
+16,619
| +90% | +$2.41M | 1.9% | 3 |
|
|
2021
Q4 | $2.5M | Hold |
18,428
| – | – | 1.23% | 15 |
|
|
2021
Q3 | $1.97M | Hold |
18,428
| – | – | 0.96% | 28 |
|
|
2021
Q2 | $2.08M | Sell |
18,428
-1,364
| -7% | -$154K | 1.06% | 18 |
|
|
2021
Q1 | $2.1M | Buy |
+19,792
| New | +$2.12M | 1.07% | 18 |
|
|
2020
Q4 | – | Sell |
-21,776
| Closed | -$1.91M | – | 87 |
|
|
2020
Q3 | $1.91M | Buy |
21,776
+7,812
| +56% | +$735K | 1.03% | 52 |
|
|
2020
Q2 | $1.38M | Sell |
13,964
-620
| -4% | -$54.6K | 1.31% | 24 |
|
|
2020
Q1 | $1.06M | Sell |
14,584
-1,488
| -9% | -$127K | 1.21% | 36 |
|
|
2019
Q4 | $1.43M | Sell |
16,072
-372
| -2% | -$30.9K | 1.13% | 19 |
|
|
2019
Q3 | $1.25M | Buy |
16,444
+6,287
| +62% | +$431K | 1.03% | 48 |
|
|
2019
Q2 | $739K | Sell |
10,157
-1,155
| -10% | -$90.8K | 0.61% | 96 |
|
|
2019
Q1 | $912K | Buy |
11,312
+539
| +5% | +$44.1K | 0.71% | 96 |
|
|
2018
Q4 | $993K | Buy |
+10,773
| New | +$947K | 0.91% | 81 |
|
|
2017
Q3 | $371K | Buy |
+4,179
| New | +$318K | 1.16% | 11 |
|
|
2016
Q1 | – | Sell |
-39,220
| Closed | -$2.32M | – | 101 |
|
|
2015
Q4 | $2.32M | Buy |
+39,220
| New | +$2.26M | 1.06% | 27 |
|
Other funds holding ABBV
VCM
VPM
Abacus FCF Advisors's ABBV Position: Q1 2026 in Review
Abacus FCF Advisors reduced its AbbVie (ABBV) stake by 42% in Q1 2026, selling an estimated $9.45M and leaving 59,268 shares worth $12.9M. The position accounts for 2.9% of the portfolio, ranked #8.
Abacus FCF Advisors first reported a position in ABBV in Q4 2015 and has held it in 31 quarters since. The position peaked at $29.2M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Abacus FCF Advisors held 59,268 shares of AbbVie worth $12.9M as of Q1 2026.
- Abacus FCF Advisors sold 42,595 AbbVie shares in Q1 2026, an estimated $9.45M.
- AbbVie made up 2.9% of Abacus FCF Advisors's portfolio in Q1 2026, its #8 holding.
- Abacus FCF Advisors first reported a position in AbbVie in Q4 2015 and has held it in 31 quarters since.
- Abacus FCF Advisors's AbbVie position peaked at $29.2M in Q3 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Abacus FCF Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.